Advertisement

Neurophysiology

, Volume 38, Issue 4, pp 217–227 | Cite as

Synaptic inhibition of smooth muscles of the human colon: Effects of vitamin B6 and its derivatives

  • A. V. Romanenko
  • M. M. Grusha
Article

Abstract

Spontaneous activity, which is manifested as slow depolarization waves and action potentials, is observed in most (81%) smooth muscles (SMs) of the circular layer of the human colon. Independently of the type of pathology, inhibitory junction potentials (IJPs) in SMs of various parts of the human colon are evoked by intramural stimulation; ranges of parameters of these potentials were comparable with those observed in muscle intestinal fragments isolated at a distance of several tens of centimeters from the zone of injury. In muscle strips (MSs) of such fragments, pyridoxal-5′-phosphate (PPh) applied in different concentrations caused suppression of IJPs: in the concentration of 1·10−8 to 1·10−4 M it decreased the amplitude, and in the concentrations of 1·10−5 to 1·10−4 M and 1·10−4 M, respectively, it decreased rates of the half-amplitude rise and decay of these potentials. Pyridoxal (1·10−4 M) and 4-pyridoxolic acid (1·10−4 M) also caused a drop in the amplitude of IJPs; however, these agents influenced this parameter to a lesser extent, as compared with the effect of 1·10−4 M PPh. Pyridoxine (1·10−4 M) and pyridoxamine (1·10−4 M) evoked no significant changes in the parameters of IJPs in MSs of the human colon. Our data allow us to hypothesize that the suppressing effect of PPh on IJPs is determined by the presence of a purinergic component present in non-adrenergic inhibition of SMs of the human colon.

Keywords

synaptic inhibition smooth muscles human intestine vitamin B6, pyridoxal-5-′-phosphate 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    J. D. Wood, D. H. Alpers, and P. L. R. Andrews, “Fundamentals of neurogastroenterology,” Gut, 45, Suppl. II, II6–II16 (1999).PubMedCrossRefGoogle Scholar
  2. 2.
    I. A. Vladimirova and M. F. Shuba, “Synaptic processes in smooth muscles,” Neirofiziologiya, 16, No. 3, 307–319 (1984).Google Scholar
  3. 3.
    M. F. Shuba, I. A. Vladimirova, T. O. Ermakova, et al., “Mechanisms of non-adrenergic synaptic transmission in smooth muscle cells of the gastrointestinal tract,” Neurophysiology, 30, Nos. 4/5, 208–212 (1998).CrossRefGoogle Scholar
  4. 4.
    V. P. Zagorodnyuk and M. F. Shuba, “Nature of non-adrenergic inhibition in smooth muscles of the human intestine,” Neirofiziologiya, 18, No. 3, 373–381 (1986).Google Scholar
  5. 5.
    M. E. Stark, A. J. Bauer, M. G. Sarr, and J. H. Szurszewski, “Nitric oxide mediates inhibitory nerve input in human and canine jejunum,” Gastroenterology, 104, No. 2, 398–409 (1993).PubMedGoogle Scholar
  6. 6.
    V. P. Zagorodnyuk, I. A. Vladimirova, S. A. Chernovoleko, and M. F. Shuba, “Study of non-adrenergic inhibition in smooth muscles of the human intestine in Hirschsprung’s disease,” Fiziol. Zh., 34, No. 5, 50–55 (1988).Google Scholar
  7. 7.
    O. M. Romanenko, M. M. Grusha, and P. D. Fomin, “Suppressing effect of pyridoxal-5′-phosphate on non-adrenergic synaptic inhibition of smooth muscles of the human small intestine,” Fiziol. Zh., 52, No. 1, 62–70 (2006).PubMedGoogle Scholar
  8. 8.
    A. V. Romanenko, P. D. Fomin, and M. M. Grusha, “Effect of pyridoxal-5′-phosphate on electrical and contractile activity of human smooth muscles,” Dop. Nats. Akad. Nauk Uktainy, No. 8, 199–203 (2000).Google Scholar
  9. 9.
    T. Asakura, N. Takahashi, T. Hirakawa, et al., “Regulation of pyridoxal-5′-phosphate level by biogenic amines in mouse brain,” Neurochem. Res., 21, No. 1, 47–50 (1996).PubMedCrossRefGoogle Scholar
  10. 10.
    B. E. Jones and A. C. Cuello, “Afferents to the basal forebrain cholinergic cell area from pontomesencephalic-catecholamine, serotonin, and acetylcholine neurons,” Neuroscience, 31, 37–61 (1989).PubMedCrossRefGoogle Scholar
  11. 11.
    G. Lambrecht, K. Braun, M. Damer, et al., “Structure-activity relationships of suramin and pyridoxal-5′-phosphate derivatives as P2 receptors antagonists,” Curr. Pharm. Des., 8, No. 26, 2371–2399 (2002).PubMedCrossRefGoogle Scholar
  12. 12.
    V. Ralevic and G. Burnstock, “Receptors for purines and pyrimidines,” Pharmacol. Rev., 50, No. 3, 413–492 (1998).PubMedGoogle Scholar
  13. 13.
    D. J. Trezise, N. J. Bell, B. S. Khakh, et al., “P2 purinoceptor antagonist properties of pyridoxal-5-phosphate,” Eur. J. Pharmacol., 259, No. 3, 295–300 (1994).PubMedGoogle Scholar
  14. 14.
    D. P. Artemenko V. A. Buryi, I. A. Vladimirova, and M. F. Shuba, “Modification of a single sucrose-gap technique,” Fiziol. Zh., 28, No. 3, 374–380 (1982).PubMedGoogle Scholar
  15. 15.
    V. A. Kokunin, “Statistical treatment of the data of small experimental samplings,” Ukr. Biokhim. Zh., 47, No. 1, 776–791 (1975).PubMedGoogle Scholar
  16. 16.
    O. P. Mintser, B. N. Ugarov, and V. V. Vlasov, Techniques of Processing of Medical Information [in Russian], Vyshcha Shkola, Kyiv (1991).Google Scholar
  17. 17.
    L. Xue, G. Farrugia, M. G. Sarr, and J. H. Szurszewski, “ATP is a mediator of the fast inhibitory junction potential in human jejunal circular smooth muscle,” Am. J. Physiol., 276, No. 39, G1373–G1379 (1999).Google Scholar
  18. 18.
    I. A. Vladimirova, V. P. Zagorodnyuk, I. V. Ostrovsky, et al., “Specifics of ultrasound-induced changes in synaptic processes mediated by different transmitters in smooth muscles,” Neurophysiology, 25, No. 4, 251–255 (1993).CrossRefGoogle Scholar
  19. 19.
    V. I. Skok and M. F. Shuba, Neuromuscular Physiology [in Russian], Vyshcha Shkola, Kyiv (1986).Google Scholar
  20. 20.
    T. D. Westfall, S. Sarkar, N. Ramphir, et al., “Characterization of the ATPase released during sympathetic nerve stimulation of the guinea-pig isolated vas deferens,” Br. J. Pharmacol., 129, 684–1688 (2000).CrossRefGoogle Scholar
  21. 21.
    M. F. Shuba, I. A. Vladimirova, and I. B. Philyppov, “Mechanisms of the inhibitory action of neurotransmitters on smooth muscles,” Neurophysiology, 35, Nos. 3/4, 224–233 (2003).CrossRefGoogle Scholar
  22. 22.
    A. V. Romanenko, V. M. Gnatenko, and M. M. Grusha, “Effects of pyridoxal 5′-phosphate on synaptic transmission in smooth muscle,” Neurophysiology, 32, No. 5, 305–311 (2000).CrossRefGoogle Scholar
  23. 23.
    V. Zagorodnyuk, P. Santicioli, C. A. Maggi, and A. Giachetti, “The possible role of ATP and PACAP as mediators of apamin-sensitive NANC inhibitory junction potentials in circular muscle of guinea-pig colon,” Br. J. Pharmacol., 119, No. 5, 779–786 (1996).PubMedGoogle Scholar
  24. 24.
    V. Zagorodnyuk and C. A. Maggi, “Pharmacological evidence for the existence of P2 receptors in the circular muscle of guinea-pig colon,” Br. J. Pharmacol., 123, No. 1, 122–128 (1998).PubMedCrossRefGoogle Scholar
  25. 25.
    M. V. Bor, H. Refsum, M. R. Bisp, et al., “Plasma vitamin B6 vitamers before and after oral vitamin B6 treatment: a randomized placebo-controlled study,” Clin. Chemistry, 49, No. 1, 155–161 (2003).CrossRefGoogle Scholar
  26. 26.
    A. Hamfeldt and L. Soderhjelm, “Vitamin B6 and aging,” in: Clinical and Physiological Applications of Vitamin B 6, J. E. Leklem and A. R. Reynoles, New York (1988), pp. 95–107.Google Scholar
  27. 27.
    C. L. Deitrick, R. E. Katholi, D. J. Huddleston, et al., “Clinical adaptation of a high-performance liquid chromatographic method for the assay of pyridoxal 5′-phosphate in human plasma,” J. Chromatogr., Ser. B., 751, 383–387 (2001).Google Scholar
  28. 28.
    V. V. Kushnir, I. V. Dombrovskii, and M. P. Kushnir, “Laboratory diagnostics of hypovitaminosis in patients suffering from diseases of the digestive system,” in: Summaries of Reports of III Conference of the Republican Scientific Society of Physician-Laboratory Assistants [in Russian], Kyiv (1983), pp. 133–134.Google Scholar
  29. 29.
    I. D. Uspenskaya, O. A. Vrzhesinskaya, V. M. Kodentsova, et al., “Provision with vitamins of children suffering from chronic enteritis and celiac disease,” Ross. Zh. Gastroenterol. Gematol., Koloproktol., 6, No. 3, 64–66 (1996).Google Scholar
  30. 30.
    N. M. Khmelevskii and V. Ya. Kirshenblat, “Diabetic gastroparesis stimulating acute intestinal obstruction,” Vracheb. Delo, No. 4, 58–60 (1981).Google Scholar
  31. 31.
    I. T. Lott, T. Coulombe, R. V. Di Paolo, et al., “Vitamin B6-dependent seizures: pathology and chemical findings in brain,” Neurology, 28, No. 1, 47–54 (1978).PubMedGoogle Scholar
  32. 32.
    T. Goto, N. Matsuo, and T. Takahashi, “CSF glutamate/GABA concentrations in pyridoxine-dependent seizures: etiology of pyridoxine-dependent seizures and the mechanisms of pyridoxine action in seizure control,” Brain Dev., 23, No. 1, 24–29 (2001).PubMedCrossRefGoogle Scholar
  33. 33.
    P. Baxter, “Pyridoxine-dependent seizures: a clinical and biochemical conundrum,” Biochim. Biophys. Acta, 1647, Nos. 1/2, 36–41 (2003).PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2006

Authors and Affiliations

  1. 1.Bogomolets National Medical UniversityMinistry of Public Health of UkraineKyivUkraine

Personalised recommendations